Acceleron Pharma Inc. (XLRN) Set to Announce Earnings on Wednesday
Acceleron Pharma Inc. (NASDAQ:XLRN) will be posting its quarterly earnings results before the market opens on Wednesday, August 2nd. Analysts expect Acceleron Pharma to post earnings of ($0.63) per share for the quarter.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.08. The business had revenue of $3.71 million for the quarter, compared to analyst estimates of $3.38 million. Acceleron Pharma had a negative net margin of 659.04% and a negative return on equity of 38.57%. The firm’s quarterly revenue was down 79.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.13 earnings per share. On average, analysts expect Acceleron Pharma to post $-2.51 EPS for the current fiscal year and $-2.16 EPS for the next fiscal year.
Acceleron Pharma Inc. (NASDAQ:XLRN) opened at 32.22 on Wednesday. Acceleron Pharma Inc. has a one year low of $23.07 and a one year high of $41.69. The firm’s market capitalization is $1.24 billion. The stock’s 50 day moving average is $30.95 and its 200-day moving average is $28.15.
In other news, SVP Ravindra Kumar sold 937 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $29,984.00. Following the sale, the senior vice president now owns 96,264 shares of the company’s stock, valued at approximately $3,080,448. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin F. Mclaughlin sold 34,400 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $1,100,800.00. Following the sale, the chief financial officer now directly owns 80,950 shares in the company, valued at approximately $2,590,400. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,337 shares of company stock worth $1,642,784. Insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Acceleron Pharma Inc. (XLRN) Set to Announce Earnings on Wednesday” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/26/acceleron-pharma-inc-xlrn-set-to-announce-earnings-on-wednesday.html.
Several brokerages recently commented on XLRN. Piper Jaffray Companies increased their price objective on shares of Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Friday, June 23rd. BidaskClub raised shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 12th. JMP Securities reissued an “outperform” rating and set a $39.00 price objective on shares of Acceleron Pharma in a research report on Monday, May 1st. Finally, Credit Suisse Group reissued a “buy” rating and set a $46.00 price objective on shares of Acceleron Pharma in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $41.73.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.